Rare Disease Clinical Trials LATAM: Regulatory Incentives & Patient Access
This article delves into the regulatory landscape of rare disease clinical trials in LATAM, highlighting incentives that improve patient access to essential therapies.
Quick Answer
This article delves into the regulatory landscape of rare disease clinical trials in LATAM, highlighting incentives that improve patient access to essential therapies.
Key Questions
- What does ANMAT Disposition 7516/2025 change for clinical trials in Argentina?
- How does ICH E6 (R3) alignment benefit rare disease research specifically?
- Which LATAM regulators oversee rare disease clinical trials?
- What expedited pathways exist for rare disease trials under the new framework?
- When do the new ICH E6 (R3) standards take effect?
Argentina's ANMAT adopted Disposition 7516/2025 on December 1, 2025. The rule replaces the 2010 framework with ICH E6 (R3) Good Clinical Practice standards. Sponsors gain faster approval for rare disease trials through risk-based designs and priority pathways for orphan drugs. Argentina now competes for global clinical research in Latin America.
Contents12 sections
Key Takeaways
- Regulatory alignment: ANMAT Disposition 7516/2025 adopts ICH E6 (R3) standards. The rule took effect December 1, 2025. It replaces Disposition 6677/2010. Global regulators may now accept trial data from Argentina.
- Rare disease provisions: The framework supports adaptive trial designs. Basket studies and smaller cohorts are now possible. This helps research on ultra-rare conditions with patients spread across regions.
- Expedited pathways: Differentiated evaluation timelines prioritize orphan drugs, neglected infectious diseases, and emergency protocols through pre-submission consultations.
- Regional harmonization: Argentina's adoption positions LATAM for broader ICH E6 alignment among ANVISA, COFEPRIS, INVIMA, and ISP regulators.
- Market implications: Streamlined approval processes may increase global sponsor investment in Argentina-based rare disease trials and improve patient access to investigational therapies.
What Changed Under ANMAT Disposition 7516/2025?
Argentina joined the International Council for Harmonisation (ICH) as a Regulatory Member in June 2024. Disposition 7516/2025 puts this into practice. It adopts the ICH E6 (R3) guideline starting December 1, 2025.
The new rule cancels four prior ANMAT orders: 6677/2010, 4008/2017, 9929/2019, and 2172/2025. Applications filed before December 1, 2025, keep the old rules until approved.
How Does ICH E6 (R3) Apply to Rare Disease Trials?
Rare disease research faces tough problems. Patient groups are small. It takes longer to find participants. Disease symptoms vary. Patients live far from study sites.
ICH E6 (R3) solves these problems in four ways:
- Proportionate risk management: Study design fits the risks. Smaller rare disease trials need less monitoring.
- Adaptive designs: Basket trials and response-adaptive methods work for mixed patient groups. Teams can change protocols without full resubmission.
- Data flexibility: Digital tools and remote visits cut travel for patients who live far from sites.
- Quality by design: Teams identify key data needs early. This cuts paperwork later.
Disposition 7516/2025 applies to Phase I, II, and III trials for drug registration. Bioequivalence studies and non-interventional research follow different ANMAT rules.
Which Regulators Govern Rare Disease Trials Across LATAM?
Five agencies oversee clinical trials in major Latin American markets:
| Agency | Country | Full Name | Framework |
|---|---|---|---|
| ANVISA | Brazil | Agência Nacional de Vigilância Sanitária | National GCP standards |
| COFEPRIS | Mexico | Comisión Federal para la Protección contra Riesgos Sanitarios | National GCP standards |
| ANMAT | Argentina | Administración Nacional de Medicamentos, Alimentos y Tecnología Médica | ICH E6 (R3) Dec 2025 |
| INVIMA | Colombia | Instituto Nacional de Vigilancia de Medicamentos y Alimentos | National GCP standards |
| ISP | Chile | Instituto de Salud Pública | National GCP standards |
Argentina's ICH E6 (R3) adoption helps sponsors who need global recognition for trial data. Other LATAM agencies have not announced similar adoption.
What Expedited Pathways Exist for Rare Disease Studies?
Annex III of Disposition 7516/2025 creates fast-track review. Three categories get priority:
- Orphan drugs: Products for rare diseases
- Neglected diseases: Infectious diseases with few treatments in affected regions
- Emergency protocols: Studies for public health emergencies
Pre-submission meetings are required for Phase I trials and advanced therapies. These meetings align sponsors with ANMAT on protocol design early.
ANMAT can suspend trials for non-compliance. They can reject data from poorly run studies. They can also call expert committees during review.
How Do Patient Access Programs Bridge Treatment Gaps?
Patient access programs (PAPs) play a key role in rare disease drug development. These programs provide study drugs after trials end but before commercial launch.
In Argentina, Disposition 12792/2016 sets rules for importing post-study drugs. PAPs help patients continue treatment after trials. This cuts the risk of treatment gaps.
PAPs work with the new ICH E6 (R3) rules. Patients move from trials to expanded access during regulatory review. Disposition 7516/2025 Annex II requires insurance to protect participants.
What Is the Implementation Timeline?
Disposition 7516/2025 took effect December 1, 2025. The transition works as follows:
- Applications filed on or after December 1, 2025, use ICH E6 (R3)
- Pending applications filed before December 1, 2025, use Disposition 6677/2010
- Running trials can switch to new rules or keep old rules through completion
Five annexes support the rule:
- Annex I: ICH E6 R3 GCP guidelines
- Annex II: Local requirements
- Annex III: Submission procedures
- Annex IV: Inspection protocols
- Annex V: Phase I center requirements
What Are the Market Implications for LATAM?
Argentina's rule change shifts the market for rare disease clinical trials in Latin America. Three factors drive this:
Data acceptance: ICH E6 (R3) raises the odds that U.S. FDA and European EMA will accept Argentine trial data. Global sponsors trust LATAM evidence more.
Patient access: Argentina has over 3 million rare disease patients. Brazil and Mexico have similar numbers. The new rules unlock this patient pool.
Research infrastructure: Faster approvals draw CRO investment. This builds local trial staff and sites for rare disease studies.
Argentina became an ICH Regulatory Member in June 2024. Disposition 7516/2025 puts this into action. Other LATAM agencies have not announced adoption dates.
Future Outlook: Will LATAM Regulators Harmonize?
Argentina's ICH E6 (R3) adoption may catalyze broader regional alignment. Brazil's ANVISA, Mexico's COFEPRIS, Colombia's INVIMA, and Chile's ISP maintain distinct national frameworks.
No formal timelines for ICH adoption have been announced by these regulators. However, the Pan American Health Organization (PAHO) recertified ANMAT as a Regional Reference Regulatory Authority for medicines and vaccines in 2017. This status may encourage peer agencies to evaluate similar harmonization.
Cross-border regulatory convergence would transform LATAM into a competitive destination for global rare disease trials. Until then, Argentina's ICH E6 (R3) alignment provides sponsors a harmonized regulatory environment within the region.
Key Challenges Remain
Regulatory advancement does not resolve all operational constraints. Rare disease trials in Argentina face persistent infrastructure limitations:
- Diagnostic capacity: Specialized rare disease diagnostic facilities remain concentrated in major urban centers
- Site distribution: Geographic distance between qualified sites and dispersed rare disease patients complicates recruitment
- Cross-border data: Data sharing agreements between LATAM regulators require development for multi-country rare disease protocols
These operational factors persist alongside regulatory improvements. Sponsors must evaluate Argentina's ICH E6 (R3) harmonization alongside infrastructure readiness when planning orphan drug development programs.
Frequently Asked Questions
What does ANMAT Disposition 7516/2025 change for clinical trials in Argentina?
ANMAT Disposition 7516/2025 replaces the 2010 regulatory framework with ICH E6 (R3) Good Clinical Practice standards effective December 1, 2025. The reform adopts risk-proportionate trial design, streamlines documentation requirements, and establishes expedited evaluation pathways for rare disease and orphan drug protocols.
How does ICH E6 (R3) alignment benefit rare disease research specifically?
ICH E6 (R3) supports adaptive trial designs and accommodates smaller patient populations critical for rare disease studies. The framework enables response-adaptive randomization and basket trials while maintaining rigorous safety oversight through proportionate risk management.
Which LATAM regulators oversee rare disease clinical trials?
Five major regulatory bodies govern rare disease trials across Latin America: ANVISA in Brazil, COFEPRIS in Mexico, ANMAT in Argentina, INVIMA in Colombia, and ISP in Chile. Each operates under distinct frameworks, though Argentina's ICH E6 (R3) adoption signals convergence toward international standards.
What expedited pathways exist for rare disease trials under the new framework?
ANMAT Disposition 7516/2025 establishes differentiated evaluation timelines with priority review for orphan drugs, neglected infectious diseases, and emergency protocols. Pre-submission consultations and abbreviated processes for adaptive designs reduce time-to-first-patient enrollment.
When do the new ICH E6 (R3) standards take effect?
The regulation took effect December 1, 2025. Pending applications submitted before that date continue under the previous Disposition 6677/2010 framework through resolution.
Primary Sources
- ANMAT Disposition 7516/2025 — Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Approves Good Clinical Practice norms, evaluation and oversight of clinical pharmacology studies for registration purposes. Adopts ICH E6 (R3). Effective December 1, 2025.
- Boletín Oficial de la República Argentina — Publication of Disposition 7516/2025. October 9, 2025. Boletín Oficial número 35767, página 57.
- ICH E6 (R3) Guideline — International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Good Clinical Practice guideline adopted by ANMAT effective January 6, 2025.
- ANMAT Disposition 12792/2016 — InfoLeg. Establishes procedures for post-study treatment access importation. November 17, 2016.
- Prior ANMAT Clinical Trial Framework — Disposition 6677/2010, repealed by Disposition 7516/2025 effective December 1, 2025.
This article follows our editorial standards. Report a correction via editorial contact.
Continue Your Research
Industry Reports & Whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…